IDEAYA Biosciences Q3 2025 Earnings Report

IDEAYA Biosciences EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.12
• Beat/Miss: N/A
• One Year Ago EPS: N/A

IDEAYA Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $59.98 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

IDEAYA Biosciences Announcement Details

• Quarter: Q3 2025
• Date: 11/3/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, November 4, 2025
• Conference Call Time: 12:30PM ET

IDEAYA Biosciences (NASDAQ:IDYA) is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies. This platform supports the rapid progression of drug candidates from target validation through early clinical development. IDEAYA has entered strategic collaborations with established pharmaceutical partners to expand the reach of its synthetic lethality portfolio, leveraging complementary expertise in drug discovery, development, and commercialization.

Founded in 2016 and headquartered in South San Francisco, California, IDEAYA maintains research operations in the United States and collaborates with leading academic institutions and industry organizations worldwide. The company’s management team comprises experienced biopharmaceutical executives and oncology researchers who guide its mission to deliver precision medicines to patients with high-need cancers. IDEAYA continues to build on its scientific foundation to bring forward innovative treatments that address genetically defined subsets of tumors.